Eckardt Treuter

Eckardt Treuter

Auto-generated profile, based on publicly available information

Eckardt Treuter

Department of Medicine Huddinge, Unit for Gastroenterology and Nutrition, Karolinska Institutet, Huddinge, Sweden

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2010 in Genes & Development
Verified
Journal Article
Closed access
PDF file
NVNicolas Venteclef
Nicolas Venteclef
TJTomas Jakobsson
Tomas Jakobsson
AEAnna Ehrlund
Anna Ehrlund
ADAnastasios Damdimopoulos
Anastasios Damdimopoulos
LMLaura Mikkonen
Laura Mikkonen
ETEckardt Treuter
Eckardt Treuter
The orphan receptor LRH-1 and the oxysterol receptors LXRα and LXRβ are established transcriptional regulators of lipid metabolism that appear to control inflammatory processes. Here, we investigate the anti-inflammatory actions of these nuclear receptors in the hepatic acute phase response (APR). We report that selective synthetic agonists induce SUMOylation-dependent recruitment of either LRH-1 or LXR to hepatic APR promoters and prevent the clearance of the N-CoR corepressor complex upon cytokine stimulation. Investigations of the APR in vivo, using LXR knockout mice, indicate that the anti-inflammatory actions of LXR agonists are triggered selectively by the LXRβ subtype. We further find that hepatic APR responses in small ubiquitin-like modifier-1 (SUMO-1) knockout mice are increased, which is due in part to diminished LRH-1 action at APR promoters. Finally, we provide evidence that the metabolically important coregulator GPS2 functions as a hitherto unrecognized transrepression mediator of interactions between SUMOylated nuclear receptors and the N-CoR corepressor complex. Our study extends the knowledge of anti-inflammatory mechanisms and pathways directed by metabolic nuclear receptor–corepressor networks to the control of the hepatic APR, and implies alternative pharmacological strategies for the treatment of human metabolic diseases associated with inflammation.

1 August 2011 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
ETEckardt Treuter
Eckardt Treuter
NVNicolas Venteclef
Nicolas Venteclef

10 December 2012 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ATAmine Toubal
Amine Toubal
KCKarine Clément
Karine Clément
RFRongrong Fan
Rongrong Fan
PAPatricia Ancel
Patricia Ancel
VPVeronique Pelloux
Veronique Pelloux
NVNicolas Venteclef
Nicolas Venteclef
Low-grade chronic inflammation is a major characteristic of obesity and results from deregulated white adipose tissue function. Consequently, there is interest in identifying the underlying regulatory mechanisms and components that drive adipocyte inflammation. Here, we report that expression of the transcriptional corepressor complex subunits GPS2 and SMRT was significantly reduced in obese adipose tissue, inversely correlated to inflammatory status, and was restored upon gastric bypass surgery–induced weight loss in morbid obesity. These alterations correlated with reduced occupancy of the corepressor complex at inflammatory promoters, providing a mechanistic explanation for elevated inflammatory transcription. In support of these correlations, RNAi-mediated depletion of GPS2 and SMRT from cultured human adipocytes promoted derepression of inflammatory transcription and elevation of obesity-associated inflammatory markers, such as IL-6 and MCP-1. Furthermore, we identified a regulatory cascade containing PPARγ and TWIST1 that controlled the expression of GPS2 and SMRT in human adipocytes. These findings were clinically relevant, because treatment of diabetic obese patients with pioglitazone, an antidiabetic and antiinflammatory PPARγ agonist, restored expression of TWIST1, GPS2, and SMRT in adipose tissue. Collectively, our findings identify alterations in a regulatory transcriptional network in adipocytes involving the dysregulation of a specific corepressor complex as among the initiating events promoting adipose tissue inflammation in human obesity.

31 January 2012 in BMC Genomics
Verified
Journal Article
Open access
PDF file
PPPetri Pehkonen
Petri Pehkonen
LWLynn Welter-Stahl
Lynn Welter-Stahl
JDJanine Diwo
Janine Diwo
JRJussi Ryynänen
Jussi Ryynänen
AWAnke Wienecke-Baldacchino
Anke Wienecke-Baldacchino
Carsten CarlbergCarsten Carlberg
Carsten Carlberg
Background: The liver X receptors (LXRs) are oxysterol sensing nuclear receptors with multiple effects on metabolism and immune cells. However, the complete genome-wide cistrome of LXR in cells of human origin has not yet been provided.Results: We performed ChIP-seq in phorbol myristate acetate-differentiated THP-1 cells (macrophage-type) after stimulation with the potent synthetic LXR ligand T0901317 (T09). Microarray gene expression analysis was performed in the same cellular model. We identified 1357 genome-wide LXR locations (FDR < 1%), of which 526 were observed after T09 treatment.De novoanalysis of LXR binding sequences identified a DR4-type element as the major motif. On mRNA level T09 up-regulated 1258 genes and repressed 455 genes. Our results show that LXR actions are focused on 112 genomic regions that contain up to 11 T09 target genes per region under the control of highly stringent LXR binding sites with individual constellations for each region. We could confirm that LXR controls lipid metabolism and transport and observed a strong association with apoptosis-related functions.Conclusions: This first report on genome-wide binding of LXR in a human cell line provides new insights into the transcriptional network of LXR and its target genes with their link to physiological processes, such as apoptosis.The gene expression microarray and sequence data have been submitted collectively to the NCBI Gene Expression Omnibushttp://www.ncbi.nlm.nih.gov/geounder accession number GSE28319.

24 May 2023 in Nature
Verified
Journal Article
Closed access
PDF file
APAna Paredes
Ana Paredes
RJRaquel Justo
Raquel Justo
DJDaniel Jiménez-Blasco
Daniel Jiménez-Blasco
VNVanessa Núñez
Vanessa Núñez
ICIrene Calero
Irene Calero
MRMercedes Ricote
Mercedes Ricote

11 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NLNing Liang
Ning Liang
ADAnastasius Damdimopoulos
Anastasius Damdimopoulos
SGSaioa Goñi
Saioa Goñi
ZHZhiqiang Huang
Zhiqiang Huang
LVLise-Lotte Vedin
Lise-Lotte Vedin
RFRongrong Fan
Rongrong Fan
Obesity triggers the development of non-alcoholic fatty liver disease (NAFLD), which involves alterations of regulatory transcription networks and epigenomes in hepatocytes. Here we demonstrate that G protein pathway suppressor 2 (GPS2), a subunit of the nuclear receptor corepressor (NCOR) and histone deacetylase 3 (HDAC3) complex, has a central role in these alterations and accelerates the progression of NAFLD towards non-alcoholic steatohepatitis (NASH). Hepatocyte-specific Gps2 knockout in mice alleviates the development of diet-induced steatosis and fibrosis and causes activation of lipid catabolic genes. Integrative cistrome, epigenome and transcriptome analysis identifies the lipid-sensing peroxisome proliferator-activated receptor α (PPARα, NR1C1) as a direct GPS2 target. Liver gene expression data from human patients reveal that Gps2 expression positively correlates with a NASH/fibrosis gene signature. Collectively, our data suggest that the GPS2-PPARα partnership in hepatocytes coordinates the progression of NAFLD in mice and in humans and thus might be of therapeutic interest.